# Supplemental Digital Content 6. Geometric mean concentrations for each of the pertussis components 28 days after the Tdap dose in the concomitant and sequential groups in baseline dengue seropositive participants by age group (FAS)

|  |  |  |
| --- | --- | --- |
|  | **Concomitant** | **Sequential** |
| **ELISA-EU/mL** | **M** | **GMC** | **95% CI** | **M** | **GMC** | **95% CI** |
| **9–11 years** |  |  |  |  |  |  |
| Anti-PT | 61 | 63.0 | 49.9, 79.5 | 67 | 69.8 | 52.6, 92.7 |
| Anti-FHA | 62 | 285 | 232, 350 | 67 | 232 | 183, 293 |
| Anti-PRN | 62 | 45.5 | 31.4, 66.1 | 67 | 42.5 | 29.5, 61.1 |
| Anti-FIM2+3 | 62 | 571 | 380, 857 | 66 | 536 | 352, 816 |
| **12–17 years** |  |  |  |  |  |  |
| Anti-PT | 80 | 88.7 | 73.2, 108 | 75 | 119 | 98.2, 144 |
| Anti-FHA | 85 | 274 | 227, 331 | 78 | 264 | 217, 321 |
| Anti-PRN | 86 | 72.4 | 50.0, 105 | 78 | 51.3 | 34.6, 76.1 |
| Anti-FIM2+3 | 86 | 1782 | 1409, 2253 | 78 | 1697 | 1295, 2224 |
| **18–45 years** |  |  |  |  |  |  |
| Anti-PT | 78 | 62.9 | 47.6, 83.2 | 83 | 80.0 | 65.8, 97.2 |
| Anti-FHA | 81 | 240 | 199, 288 | 83 | 243 | 203, 291 |
| Anti-PRN | 82 | 66.8 | 45.0, 99.3 | 83 | 71.6 | 49.0, 104 |
| Anti-FIM2+3 | 81 | 692 | 478, 1002 | 82 | 665 | 486, 911 |
| **46–60 years** |  |  |  |  |  |  |
| Anti-PT | 82 | 50.8 | 39.3, 65.6 | 86 | 52.7 | 42.8, 65.0 |
| Anti-FHA | 81 | 298 | 250, 354 | 87 | 326 | 263, 404 |
| Anti-PRN | 82 | 28.5 | 18.5, 44.0 | 87 | 26.9 | 17.3, 41.8 |
| Anti-FIM2+3 | 81 | 307 | 213, 442 | 87 | 298 | 212, 419 |

CI, confidence interval; FIM, fimbriae types 2 and 3; FHA filamentous hemagglutinin; GMC, geometric mean concentration; M, number of participants with available data for the relevant endpoint; PRN, pertactin; PT, pertussis toxoid.